BioSpace News Archive

Pierre Fabre Laboratories announced an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform, for EBVALLO® a monotherapy already registered in the EU for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein–Barr virus positive post–transplant lymphoproliferative disease who have received at least one prior therapy.

Turnstone Biologics Corp. announced it will be presenting four posters highlighting preclinical data from its pipeline of programs, including the lead clinical candidate, TIDAL-01, at the Society for Immunotherapy of Cancer 38th Annual Meeting being held November 1-5, 2023 in San Diego, California.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted eight newly-hired employees inducement options to purchase an aggregate of 77,000 shares of KalVista common stock on November 1, 2023 as inducements material to each employee entering into employment with KalVista.

Cardinal Health (NYSE: CAH) today reported first quarter fiscal 2024 revenue of $54.8 billion, an increase of 10% from the first quarter of last year.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.

Plus Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to rhenium obisbemeda for the treatment of breast cancer with leptomeningeal metastases.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124x2101.

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced new data was presented at the Dermatology Drug Development Summit (DDDS) that took place in Boston, MA, from October 31 to November 2, 2023.

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) today announced the presentation of new preclinical data from the company’s CLD-201 (SuperNova) allogeneic stem cell-based platform and announces readiness for clinical trial launch in 2024 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.